Words of wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
The University of Texas Southwestern Medical Center, Department of Urology, J8.112, Dallas, TX 75390, USA. yair.lotan@utsouthwestern.edu
Yair
Y
Lotan